1. Home
  2. RDHL vs GXAI Comparison

RDHL vs GXAI Comparison

Compare RDHL & GXAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RDHL
  • GXAI
  • Stock Information
  • Founded
  • RDHL 2009
  • GXAI 2021
  • Country
  • RDHL Israel
  • GXAI United States
  • Employees
  • RDHL N/A
  • GXAI N/A
  • Industry
  • RDHL Biotechnology: Pharmaceutical Preparations
  • GXAI
  • Sector
  • RDHL Health Care
  • GXAI
  • Exchange
  • RDHL Nasdaq
  • GXAI Nasdaq
  • Market Cap
  • RDHL 4.3M
  • GXAI 9.7M
  • IPO Year
  • RDHL N/A
  • GXAI 2023
  • Fundamental
  • Price
  • RDHL $1.91
  • GXAI $1.22
  • Analyst Decision
  • RDHL
  • GXAI
  • Analyst Count
  • RDHL 0
  • GXAI 0
  • Target Price
  • RDHL N/A
  • GXAI N/A
  • AVG Volume (30 Days)
  • RDHL 15.6K
  • GXAI 155.0K
  • Earning Date
  • RDHL 08-28-2025
  • GXAI 08-12-2025
  • Dividend Yield
  • RDHL N/A
  • GXAI N/A
  • EPS Growth
  • RDHL N/A
  • GXAI N/A
  • EPS
  • RDHL N/A
  • GXAI N/A
  • Revenue
  • RDHL $8,042,999.00
  • GXAI $27,740.00
  • Revenue This Year
  • RDHL $381.91
  • GXAI N/A
  • Revenue Next Year
  • RDHL N/A
  • GXAI N/A
  • P/E Ratio
  • RDHL N/A
  • GXAI N/A
  • Revenue Growth
  • RDHL 23.17
  • GXAI 9987.27
  • 52 Week Low
  • RDHL $1.71
  • GXAI $1.00
  • 52 Week High
  • RDHL $20.28
  • GXAI $7.50
  • Technical
  • Relative Strength Index (RSI)
  • RDHL 44.55
  • GXAI 41.52
  • Support Level
  • RDHL $2.00
  • GXAI $1.20
  • Resistance Level
  • RDHL $2.08
  • GXAI $1.65
  • Average True Range (ATR)
  • RDHL 0.10
  • GXAI 0.10
  • MACD
  • RDHL 0.01
  • GXAI -0.02
  • Stochastic Oscillator
  • RDHL 37.05
  • GXAI 8.91

About RDHL Redhill Biopharma Ltd.

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.

About GXAI Gaxos.ai Inc.

Gaxos.AI Inc is revolutionizing the way humans interact with artificial intelligence. The company offers applications related to mental and physical well-being, coaching, and gaming. The group is committed to tackling contemporary challenges such as how to live healthier and how to live longer. In addition to offering human-centered solutions, the company uses empathetic and AI technologies.

Share on Social Networks: